Inhibition of human esophageal squamous cell carcinomas by targeted silencing of tumor enhancer genes: an overview

Cancer Biology and Medicine

Volumn 11, Issue 2, 2014, Pages 78-85

  Islamian, Jalil Pirayesh ^a   Mohammadi, Mohsen ^b   Baradaran, Behzad ^a  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Esophageal carcinoma; Ionizing radiation (IR); Oncogene; SiRNA; Targeted therapy

Indexed keywords

MESSENGER RNA; SMALL INTERFERING RNA;

APOPTOSIS; CELL PROLIFERATION; CHROMOSOME 11Q; CHROMOSOME 13Q; CHROMOSOME 1P; CHROMOSOME 3P; CHROMOSOME 4; CHROMOSOME 5Q; DNA METHYLATION; ENHANCER REGION; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; GENE AMPLIFICATION; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; HETEROZYGOSITY LOSS; HUMAN; MAMMAL CELL; REVIEW; RNA INTERFERENCE; TUMOR CELL; TUMOR GENE; TUMOR SUPPRESSOR GENE;

EID: 84903908992     PISSN: 20953941     EISSN: None     Source Type: Journal    
DOI: 10.7497/j.issn.2095-3941.2014.02.002     Document Type: Review

References (87)

1. Parkin D M, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Socialstyrelsen. Cancer incidence in Sweden 2003. In: The National Board of Health and Welfare; Centre for Epidemiology. Official Statistics of Sweden. Stockholm: 2005.
3. Enzinger P C, Mayer R J. Esophageal cancer. N Engl J Med 2003;349:2241-2252.
4. Stoner G D, Gupta A. Etiology and chemoprevention of esophageal squamous cell carcinoma. Carcinogenesis 2001;22:1737-1746.
5. Pommier R F, Vetto J T, Ferris B L, Wilmarth T J. Relationships between operative approaches and outcomes in esophageal cancer. Am J Surg 1998;175:422-425.
6. Panettiere F J, Leichman L P, Tilchen E J, Chen T T. Chemotherapy for advanced epidermoid carcinoma of the esophagus with single-agent cisplatin: final report on a Southwest Oncology Group study. Cancer Treat Rep 1984;68:1023-1024.
7. Dinwoodie W R, Bartolucci A A, Lyman G H, Velez-Garcia E, Martelo O J, Sarma P R. Phase II evaluation of cisplatin, bleomycin, Cancer Study Group Trial. Cancer Treat Rep 1986;70:267-270.
8. Bleiberg H, Conroy T, Paillot B, Lacave A J, Blijham G, Jacob J H, et al. Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer 1997;33:1216-1220.
9. Wadler S, Haynes H, Beitler J J, Hu X, Fell S, Camacho M, et al. Phase II clinical trial with 5-fluorouracil, recombinant interferon-alpha-2b, and cisplatin for patients with metastatic or regionally advanced carcinoma of the esophagus. Cancer 1996;78:30-34.
10. Ghilotti M, Pierotti M A, Gariboldi M. Molecular markers for prediction of risk of radiation-related injury to normal tissue. JNAI 2010;1:e11.
11. Park J C, Moon C. Gene therapy for esophageal cancer. Cancer Ther 2008;6:35-46.
12. Nakanoko T, Saeki H, Morita M, Nakashima Y, Ando K, Oki E, et al. Rad51 expression is a useful predictive factor for the efficacy of neoadjuvant chemoradiotherapy in squamous cell carcinoma of the esophagus. Ann Surg Oncol 2014;21:597-604.
13. Posner M, Forastiere A, Minsky B. Cancer of the esophagus. In: DeVita VT, Jr, Hellman S, Rosenberg SA. eds. Cancer Principles & Practices of Oncology. 7th ed. Philadelphia: Lippincott Williams & Wilkins; 2005: 861-909.
14. Feinberg A P. The epigenetics of cancer etiology. Semin Cancer Biol 2004;14:427-432.
15. Leu C M, Chang C, Hu C. Epidermal growth factor (EGF) suppresses staurosporine-induced apoptosis by inducing mcl-1 via the mitogen-activated protein kinase pathway. Oncogene 2000;19:1665-1675.
16. Akimoto T, Nonaka T, Harashima K, Ishikawa H, Sakurai H, Mitsuhashi N. Selective inhibition of survival signal transduction pathways enhanced radiosensitivity in human esophageal cancer cell lines in vitro. Anticancer Res 2004;24:811-819.
17. Okamoto H, Fujishima F, Nakamura Y, Zuguchi M, Miyata G, Kamei T, et al. Murine double minute 2 and its association with chemoradioresistance of esophageal squamous cell carcinoma. Anticancer Res 2013;33:1463-1471.
18. Yuan Y, Liao Y M, Hsueh C T, Mirshahidi H R. Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP. J Hematol Oncol 2011;4:16.
19. Lam A K. Molecular biology of esophageal squamous cell carcinoma. Crit Rev Oncol Hematol 2000;33:71-90.
20. Mandard A M, Hainaut P, Hollstein M. Genetic steps in the development of squamous cell carcinoma of the esophagus. Mutat Res 2000;462:335-342.
21. Song Y, Li L, Ou Y, Gao Z, Li E, Li X, et al. Identification of genomic alterations in oesophageal squamous cell cancer. Nature 2014;509:91-95.
22. Okamoto H, Fujishima F, Nakamura Y, Zuguchi M, Ozawa Y, Takahashi Y, et al. Significance of CD133 expression in esophageal squamous cell carcinoma. World J Surg Oncol 2013;11:51.
23. Nam T K, Lee J S, Kim H R, Ahn S J, Song J Y, Yoon M S. Molecular prognostic factors in rectal cancer treated by preoperative chemoradiotherapy. Oncol Lett 2010;1:23-29.
24. Hollstein M C, Peri L, Mandard A M, Welsh J A, Montesano R, Metcalf R A, et al. Genetic analysis of human esophageal tumors from two high incidence geographic areas: frequent p53 base substitutions and absence of ras mutations. Cancer Res 1991;51:4102-4106.
25. Gao H, Wang L D, Zhou Q, Hong J Y, Huang T Y, Yang C S. p53 tumor suppressor gene mutation in early esophageal precancerous lesions and carcinoma among high-risk populations in Henan, China. Cancer Res 1994;54:4342-4346.
26. Xing E P, Nie Y, Wang L D, Yang G Y, Yang C S. Aberrant methylation of p16INK4a and deletion of p15INK4b are frequent events in human esophageal cancer in Linxian, China. Carcinogenesis 1999;20:77-84.
27. Xu X C, Liu X, Tahara E, Lippman S M, Lotan R. Expression and up-regulation of retinoic acid receptor-beta is associated with retinoid sensitivity and colony formation in esophageal cancer cell lines. Cancer Res 1999;59:2477-2483.
28. Jiang W, Zhang Y J, Kahn S M, Hollstein M C, Santella R M, Lu S H, et al. Altered expression of the cyclin D1 and retinoblastoma genes in human esophageal cancer. Proc Natl Acad Sci U S A 1993;90:9026-9030.
29. Hollstein M C, Smits A M, Galiana C, Yamasaki H, Bos J L, Mandard A, et al. Amplification of epidermal growth factor receptor gene but no evidence of ras mutations in primary human esophageal cancers. Cancer Res 1988;48:5119-5123.
30. Lu S H, Hsieh L L, Luo F C, Weinstein I B. Amplification of the EGF receptor and c-myc genes in human esophageal cancers. Int J Cancer 1988;42:502-505.
31. Guo Y J. Amplification of int-2 gene in primary esophageal carcinoma and fetal esophageal carcinoma induced by N-methyl-N-benzylnitrosamine (NMBzA). Zhonghua Zhong Liu Za Zhi 1993;15:91-93.
32. Lord R V, Salonga D, Danenberg K D, Peters J H, DeMeester T R, Park J M, et al. Telomerase reverse transcriptase expression is increased early in the Barrett's metaplasia, dysplasia, adenocarcinoma sequence. J Gastrointest Surg 2000;4:135-142.
33. Tanaka H, Kijima H, Tokunaga T, Tajima T, Himeno S, Kenmochi T, et al. Frequent expression of inducible nitric oxide synthase in esophageal squamous cell carcinomas. Int J Oncol 1999;14:1069-1073.
34. Hiyama T, Yokozaki H, Kitadai Y, Haruma K, Yasui W, Kajiyama G, et al. Overexpression of human telomerase RNA is an early event in oesophageal carcinogenesis. Virchows Arch 1999;434:483-487.
35. Raida M, Sarbia M, Clement J H, Adam S, Gabbert H E, Höffken K. Expression, regulation and clinical significance of bone morphogenetic protein 6 in esophageal squamous-cell carcinoma. Int J Cancer 1999;83:38-44.
36. Zimmermann K C, Sarbia M, Weber A A, Borchard F, Gabbert H E, Schrör K. Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res 1999;59:198-204.
37. Kimura Y, Shiozaki H, Doki Y, Yamamoto M, Utsunomiya T, Kawanishi K, et al. Cytoplasmic beta-catenin in esophageal cancers. Int J Cancer 1999;84:174-178.
38. Ishii H, Baffa R, Numata S I, Murakumo Y, Rattan S, Inoue H, et al. The FEZ1 gene at chromosome 8p22 encodes a leucine-zipper protein, and its expression is altered in multiple human tumors. Proc Natl Acad Sci U S A 1999;96:3928-3933.
39. Daigo Y, Nishiwaki T, Kawasoe T, Tamari M, Tsuchiya E, Nakamura Y. Molecular cloning of a candidate tumor suppressor gene, DLC1, from chromosome 3p21.3. Cancer Res 1999;59:1966-1972.
40. Futami T, Miyagishi M, Seki M, Taira K. Induction of apoptosis in HeLa cells with siRNA expression vector targeted against bcl-2. Nucleic Acids Res Suppl 2002;(2):251-252.
41. Jackson P K, Eldridge A G, Freed E, Furstenthal L, Hsu J Y, Kaiser B K, et al. The lore of the RINGs: substrate recognition and catalysis by ubiquitin ligases. Trends Cell Biol 2000;10:429-439.
42. Toledo F, Wahl G M. MDM2 and MDM4: p53 regulators as targets in anticancer therapy. Int J Biochem Cell Biol 2007;39:1476-82.
43. Thut C J, Goodrich J A, Tjian R. Repression of p53-mediated transcription by MDM2: a dual mechanism. Genes Dev 1997;11:1974-86.
44. Mirzayans R, Andrais B, Scott A, Wang Y W, Murray D. Ionizing radiation-induced responses in human cells with differing TP53 status. Int J Mol Sci 2013;14:22409-22435.
45. Ozaki T, Nakagawara A. p53: the attractive tumor suppressor in the cancer research field. J Biomed Biotechnol 2011;2011:603925.
46. Shen H, Maki C G. Pharmacologic activation of p53 by small-molecule MDM2 antagonists. Curr Pharm Des 2011;17:560-568.
47. van Leeuwen I M, Higgins M, Campbell J, Brown C J, McCarthy A R, Pirrie L, et al. Mechanism-specific signatures for small-molecule p53 activators. Cell Cycle 2011;10:1590-1598.
48. Wang B, Fang L, Zhao H, Xiang T, Wang D. MDM2 inhibitor Nutlin-3a suppresses proliferation and promotes apoptosis in osteosarcoma cells. Acta Biochim Biophys Sin (Shanghai) 2012;44:685-91.
49. Eads C A, Lord R V, Wickramasinghe K, Long T I, Kurumboor S K, Bernstein L, et al. Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Res 2001;61:3410-3418.
50. Hibi K, Nakamura H, Hirai A, Fujikake Y, Kasai Y, Akiyama S, et al. Loss of H19 imprinting in esophageal cancer. Cancer Res 1996;56:480-482.
51. Mori M, Inoue H, Shiraishi T, Mimori K, Shibuta K, Nakashima H, et al. Relaxation of insulin-like growth factor 2 gene imprinting in esophageal cancer. Int J Cancer 1996;68:441-446.
52. Inoue H, Mori M, Li J, Mimori K, Honda M, Nakashima H, et al. Human esophageal carcinomas frequently express the tumor-rejection antigens of MAGE genes. Int J Cancer 1995;63:523-526.
53. Mashino K, Sadanaga N, Tanaka F, Yamaguchi H, Nagashima H, Inoue H, et al. Expression of multiple cancer-testis antigen genes in gastrointestinal and breast carcinomas. Br J Cancer 2001;85:713-720.
54. Zendman A J, Ruiter D J, Van Muijen G N. Cancer/testis-associated genes: identification, expression profile, and putative function. J Cell Physiol 2003;194:272-288.
55. Maley C C, Galipeau P C, Li X, Sanchez C A, Paulson T G, Reid B J. Selectively advantageous mutations and hitchhikers in neoplasms: p16 lesions are selected in Barrett's esophagus. Cancer Res 2004;64:3414-3427.
56. Kuroki T, Trapasso F, Yendamuri S, Matsuyama A, Alder H, Mori M, et al. Promoter hypermethylation of RASSF1A in esophageal squamous cell carcinoma. Clin Cancer Res 2003;9:1441-1445.
57. Wang Y, Fang M Z, Liao J, Yang G Y, Nie Y, Song Y, et al. Hypermethylation-associated inactivation of retinoic acid receptor beta in human esophageal squamous cell carcinoma. Clin Cancer Res 2003;9:5257-5263.
58. Si H X, Tsao S W, Lam K Y, Srivastava G, Liu Y, Wong Y C, et al. E-cadherin expression is commonly downregulated by CpG island hypermethylation in esophageal carcinoma cells. Cancer Lett 2001;173:71-78.
59. Hasan R, Chauhan S S, Sharma R, Ralhan R. siRNA-mediated downregulation of TC21 sensitizes esophageal cancer cells to cisplatin. World J Gastroenterol 2012;18:4127-4135.
60. Eads C A, Lord R V, Kurumboor S K, Wickramasinghe K, Skinner M L, Long T I, et al. Fields of aberrant CpG island hypermethylation in Barrett's esophagus and associated adenocarcinoma. Cancer Res 2000;60:5021-5026.
61. Zambon A, Mandruzzato S, Parenti A, Macino B, Dalerba P, Ruol A, et al. MAGE, BAGE, and GAGE gene expression in patients with esophageal squamous cell carcinoma and adenocarcinoma of the gastric cardia. Cancer 2001;91:1882-1888.
62. Akcakanat A, Kanda T, Koyama Y, Watanabe M, Kimura E, Yoshida Y, et al. NY-ESO-1 expression and its serum immunoreactivity in esophageal cancer. Cancer Chemother Pharmacol 2004;54:95-100.
63. Schrump D S, Chen G A, Consuli U, Jin X, Roth J A. Inhibition of esophageal cancer proliferation by adenovirally mediated delivery of p16INK4. Cancer Gene Ther 1996;3:357-364.
64. Ishii H, Dumon K R, Vecchione A, Trapasso F, Mimori K, Alder H, et al. Effect of adenoviral transduction of the fragile histidine triad gene into esophageal cancer cells. Cancer Res 2001;61:1578-1584.
65. Noguchi T, Takeno S, Kimura Y, Uchida Y, Daa T, Yokoyama S, et al. FHIT expression and hypermethylation in esophageal squamous cell carcinoma. Int J Mol Med 2003;11:441-447.
66. Brock M V, Gou M, Akiyama Y, Muller A, Wu T T, Montgomery E, et al. Prognostic importance of promoter hypermethylation of multiple genes in esophageal adenocarcinoma. Clin Cancer Res 2003;9:2912-2919.
67. Yakushiji T, Uzawa K, Shibahara T, Noma H, Tanzawa H. Over-expression of DNA methyltransferases and CDKN2A gene methylation status in squamous cell carcinoma of the oral cavity. Int J Oncol 2003;22:1201-1207.
68. Toh Y, Yamamoto M, Endo K, Ikeda Y, Baba H, Kohnoe S, et al. Histone H4 acetylation and histone deacetylase 1 expression in esophageal squamous cell carcinoma. Oncol Rep 2003;10:333-338.
69. Schrump D S, Nguyen D M. Targeting the epigenome for the treatment and prevention of lung cancer. Semin Oncol 2005;32:488-502.
70. Yu X, Guo Z S, Marcu M G, Neckers L, Nguyen D M, Chen G A, et al. Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J Natl Cancer Inst 2002;94:504-513.
71. Neckers L, Schulte T W, Mimnaugh E. Geldanamycin as a potential anti-cancer agent: its molecular target and biochemical activity. Invest New Drugs 1999;17:361-373.
72. Gartel A L, Tyner A L. The role of the cyclin-dependent kinase inhibitor p21 in apoptosis 1 supported in part by NIH grant R01 DK56283 (to ALT) for the p21 research and Campus Research Board and Illinois Department of Public Health Penny Severns Breast and Cervical Cancer grants (to ALG). Mol Cancer Ther 2002;1:639-649.
73. Kvols L K. Radiation sensitizers: a selective review of molecules targeting DNA and non-DNA targets. J Nucl Med 2005;46:187S-190S.
74. Abdelrahim M, Safe S, Baker C, Abudayyeh A. RNAi and cancer: Implications and applications. J RNAi Gene Silencing 2006;2:136-145.
75. Schrump D S, Nguyen D M. Novel molecular targeted therapy for esophageal cancer. J Surg Oncol 2005;92:257-261.
76. Khodarev N N, Beckett M, Labay E, Darga T, Roizman B, Weichselbaum R R. STAT1 is overexpressed in tumors selected for radioresistance and confers protection from radiation in transduced sensitive cells. Proc Natl Acad Sci U S A 2004;101:1714-1719.
77. Ogawa R, Ishiguro H, Kuwabara Y, Kimura M, Mitsui A, Mori Y, et al. Identification of candidate genes involved in the radiosensitivity of esophageal cancer cells by microarray analysis. Dis Esophagus 2008;21:288-297.
78. Wang X C, Wang W, Zhang Z B, Zhao J, Tan X G, Luo J C. Overexpression of miRNA-21 promotes radiation-resistance of non-small cell lung cancer. Radiat Oncol 2013;8:146.
79. Arora S, Mathew R, Mathur M, Chattopadhayay T K, Ralhan R. Alterations in MDM2 expression in esophageal squamous cell carcinoma: relationship with p53 status. Pathol Oncol Res 2001;7:203-208.
80. Liu T G, Yin J Q, Shang B Y, Min Z, He H W, Jiang J M, et al. Silencing of hdm2 oncogene by siRNA inhibits p53-dependent human breast cancer. Cancer Gene Ther 2004;11:748-756.
81. Perry M E. Mdm2 in the response to radiation. Mol Cancer Res 2004;2:9-19.
82. Farhadi M, Tahmasebi Z, Merat S, Kamangar F, Nasrollahzadeh D, Malekzadeh R. Human papillomavirus in squamous cell carcinoma of esophagus in a high-risk population. World J Gastroenterol 2005;11:1200-1203.
83. Matsuyama A, Inoue H, Shibuta K, Tanaka Y, Barnard G F, Sugimachi K, et al. Hepatoma-derived growth factor is associated with reduced sensitivity to irradiation in esophageal cancer. Cancer Res 2001;61:5714-5717.
84. Xie Y E, Tang E J, Zhang D R, Ren B X. Down-regulation of Bcl-XL by RNA interference suppresses cell growth and induces apoptosis in human esophageal cancer cells. World J Gastroenterol 2006;12:7472-7477.
85. Takahashi K, Miyashita M, Makino H, Akagi I, Orita H, Hagiwara N, et al. Expression of Akt and Mdm2 in human esophageal squamous cell carcinoma. Exp Mol Pathol 2009;87:42-47.
86. Zhou S, Ye W, Shao Q, Qi Y, Zhang M, Liang J. Prognostic significance of XIAP and NF-κB expression in esophageal carcinoma with postoperative radiotherapy. World J Surg Oncol 2013;11:288.
87. Pai S I, Lin Y Y, Macaes B, Meneshian A, Hung C F, Wu T C. Prospects of RNA interference therapy for cancer. Gene Ther 2006;13:464-477.